Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
To know about the assumptions considered for the study, Request for Free Sample Report
Also known gastric cancer, stomach cancer is a growth of cells that starts in the stomach. Stomach cancer, in most cases, occurs in the stomach body. Gastric cancer is one of the leading causes of cancer-related deaths and the fifth most common malignancy worldwide.
The growth of stomach cancer treatment market is projected to be driven by rising geriatric population, high implication of dietary changes and sedentary lifestyles. This includes smoking, excessive alcohol use, and consumption of an unhealthy diet. The incidence of stomach cancer is increasing from last few years. As per Globocan, nearly 1.1 million new cases of the stomach cancer were diagnosed worldwide in 2020. Therefore, increase in disease burden are projected to support the growth of the market during the forecast period.
Additionally, recent approvals of therapeutics for the treatment of stomach cancer treatment are project to drive the market growth during the forecast period. For instance, in April 2021, the FDA approved Opdivo (nivolumab) for the initial treatment of patients with metastatic or advanced GC/GEJC. In January 2021, the FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.
The global stomach cancer treatment market is segmented on the basis of type, disease indication, route of administration, drug class, distribution channel, and region. Based on type, the market is segmented into chemotherapy, immunotherapy, and targeted therapy. Based on disease indication, the stomach cancer treatment market is segmented into gastric cancer/gastroesophageal junction cancer and gastrointestinal stromal tumors. On the basis of drug class, the market is segmented into PD-1/PD-L1 inhibitors, hER2 antagonists, VEGFR2 antagonists, and others. On the basis of route of administration, the market is segmented into oral and injectable route of administration. On the basis of distribution channel, the market is segmented into hospital pharmacies, specialty & retail pharmacies, and others.
To know about the assumptions considered for the study, download the pdf brochure
North America is expected to dominate the stomach cancer treatment market over the forecast period. This owing to various factors such as high adoption of targeted cancer therapy and rising prevalence of gastric cancer. For instance, GLOBOCAN reported that in 2020, there were 29, 772 new gastric cancer cases in North America. According to the Canadian Cancer Society, in 2021, there were nearly 4,000 cases of stomach cancer in Canada.
Key Players operating in the stomach cancer treatment market are Novartis AG (Switzerland), Pfizer, Inc. (US), Mylan N.V. (US), F. Hoffmann La Roche Ltd. (Switzerland), Eli Lilly and Company (US), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Celltrion Healthcare Co., Ltd. (South Korea), Samsung Bioepis (South Korea), and Bristol Myers Squibb Company (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
6 STOMACH CANCER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 CHEMOTHERAPY
6.3 IMMUNOTHERAPY
6.4 TARGETED THERAPY
7 STOMACH CANCER TREATMENT MARKET, BY DISEASE INDICATION, 2020-2027 (USD MILLION)
7.1 INTRODUCTION
7.2 GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION CANCER
7.3 GASTROINTESTINAL STROMAL TUMORS
8 STOMACH CANCER TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 PD-1/PD-L1 INHIBITORS
8.3 HER2 ANTAGONISTS
8.4 VEGFR2 ANTAGONISTS
8.5 OTHERS (IF ANY)
9 STOMACH CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 ORAL
9.3 INJECTABLE
10 STOMACH CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
10.1 INTRODUCTION
10.2 HOSPITAL PHARMACIES
10.3 SPECIALTY & RETAIL PHARMACIES
10.4 OTHERS
11 STOMACH CANCER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 ROE
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF APAC
11.5 REST OF THE WORLD (ROW)
11.5.1 LATIN AMERICA
11.5.2 MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
12.4 MARKET SHARE ANALYSIS, 2021
12.5 COMPANY EVALUATION QUADRANT
12.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
12.8 COMPETITIVE SCENARIO
13 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided) *
13.1 ELI LILLY AND COMPANY
13.2 F. HOFFMANN-LA ROCHE LTD.
13.3 PFIZER INC.
13.4 NOVARTIS AG
13.5 SAMSUNG BIOEPIS
13.6 MERCK & CO., INC.
13.7 BIOCON
13.8 MYLAN N.V.
13.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.10 CELLTRION HEALTHCARE CO., LTD.
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS
14.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in Stomach Cancer Treatment Market